Mutations in the PI3K/AKT/mTOR pathway are frequent in breast cancer, and activation of this pathway via molecular aberrations in PIK3CA, PIK3CB, PIK3R1, AKT, TSC1/2, and PTEN promotes resistance to HER2-targeted therapies [39–41]. This evidence concerns the gene TSC1 and breast cancer.